Dr. Canaris: CurieDx could raise $2M for sales and fund R&D via grants
Dr. Therese Canaris · This App Detects Strep from a Selfie…What?! · May 14, 2025 · at 25:34
Dr. Therese Canaris is pitching CurieDx on The Pitch. When host Josh Muccio asks if she would consider a smaller round, she outlines an alternative fundraising plan.
0:00 / 0:12exact quote · 12.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“So, since Josh asked, yeah, if we were to do something on the order of two million, would that sound more like in range? And then what we would accomplish there is just sales, and we leave R&D stuff for federal grant funding.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Therese Canaris
CurieDx's strep diagnostic is 88% accurate, beating physician visual evaluations
“The rapid swab that you traditionally do at the doctor's office, the one that comes back in 15 minutes, that's about 95% accurate, so it's good, but it's not perfect, and, ah, the, you know, physicians are 64%, so we are around 88% right now accuracy”
Canaris: CurieDx Proof-of-Concept UTI Model Achieves 88% Accuracy
“And we have, just on the proof of concept model, we have 88% accuracy on that.”
CurieDX is raising $4M to reach 10,000 patients and secure FDA clearance
“We're now raising four million, which helps us reach our first 10,000 patients and get the strep product through FDA from a screening tool to a diagnostic.”
Advisors say enterprise health organizations evaluate strategic partnerships at 10,000 users
“We have advisors at Amazon One Medical and also Care First Blue Cross Blue Shield and feedback that they've given us is when we get into the 10,000 user range, that's when they start paying attention and looking at strategic partnerships.”
CurieDx will pivot from direct-to-consumer back to B2B in Q3 2025
“The intention is direct to consumer for the relatively short period, around six months from now, so like Q three of 25, we start pouring efforts back into the B to B component and slowly build up that urgent care and small to medium practice customer base.”